Transgene
Develops cancer immunotherapies using vaccines and oncolytic viruses.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-09-24 17:45 |
Transgene prévoit d’importants résultats cliniques d’ici fin 2024 et confirme s…
|
French | 423.0 KB | ||
| 2024-09-24 17:45 |
Availability of Transgene’s Half-Year Financial Report as of June 30, 2024
|
English | 182.1 KB | ||
| 2024-09-14 09:05 |
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Acti…
|
English | 862.3 KB | ||
| 2024-09-14 09:05 |
Le virus oncolytique BT-001 de Transgene et BioInvent montre une activité antit…
|
French | 884.3 KB | ||
| 2024-09-13 10:32 |
Franchissement de seuil
|
French | 201.8 KB | ||
| 2024-09-10 07:30 |
Transgene nomme deux experts en oncologie pour conduire sa prochaine phase d'in…
|
French | 396.6 KB | ||
| 2024-09-10 07:30 |
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of …
|
English | 369.8 KB | ||
| 2024-09-09 07:00 |
Transgene et BioInvent présentent des données cliniques prometteuses de l’essai…
|
French | 411.9 KB | ||
| 2024-09-09 07:00 |
Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncoly…
|
English | 419.8 KB | ||
| 2024-09-05 17:45 |
Transgene participera au HTID et à l’Investor Access Forum à Paris
|
French | 252.9 KB | ||
| 2024-09-05 17:45 |
Transgene to Participate in HTID Conference and Investor Access Forum in Paris
|
English | 248.7 KB | ||
| 2024-08-28 09:26 |
Franchissement de seuil
|
French | 200.1 KB | ||
| 2024-08-27 07:30 |
Transgene publie dans le JITC des données de preuve de concept préclinique du v…
|
French | 431.7 KB | ||
| 2024-08-27 07:30 |
Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 publish…
|
English | 389.3 KB | ||
| 2024-07-31 17:00 |
Transgene annonce la mise à disposition d’un prospectus dans le cadre de la co…
|
French | 363.9 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
